Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue 1, 2000, Pages 1-15

  Kaper, R F ^a   Norpoth, T ^b   Rekers, H ^a  

^a NV ORGANON   (Netherlands)

^b BAYER PHARMA AG   (Germany)

Author keywords

Bias; Confounding factors; Desogestrel; Epidemiological studies; Ethinylestradiol; Gestodene; Levonorgestrel; Oral contraceptives; Venous thromboembolism

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; HUMAN; INCIDENCE; INFORMATION PROCESSING; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOEMBOLISM;

EID: 0034031711     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180008500371     Document Type: Article

References (71)

1. 1. Keep PA van. The turbulent history of oral contraception. In Samsioe G, ed. The Pill, the Most Misunderstood Drug in the World. Carnforth, UK: Parthenon Publishing, 1991:11-20
2. 2. Rekers H, Norpoth T, Michaels MA. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies. Eur J Contracept Reprod Health Care 1996;1:21-30
3. 3. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346: 1582-8
4. 4. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93
5. 5. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995;346:1593-6
6. 6. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996;312:83-8
7. 7. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995;1:231-63
8. 8. Guillebaud J. Contraception, Your Questions Answered, 2nd ed. Edinburgh: Churchill Livingstone, 1993
9. 9. Lis Y, Spitzer W, Mann RD, et al. A concurrent cohort study of oral contraceptive users from the VAMP research bank. Pharmacoepidemiol Drug Saf 1993;2:51-63
10. 10. Poulter NR, Farley TMM, Chang CL, Marmot MG, Meirik O. Safety of combined oral contraceptive pills. Lancet 1996;347:547
11. 11. Heinemann LAJ, Lewis MA, Assmann A, Gravens L, Guggenmoos-Holzmann I. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives? Pharmacoepidemiol Drug Saf 1996;5:285-94
12. 12. Farmer RDT, Lawrenson R. Utilisation patterns of oral contraceptives in UK general practice. Contraception 1996;53:211-15
13. 13. Lunsen HW van. Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third generation progestogens. Eur J Contracept Reprod Health Care 1996;1:39-45
14. 14. Jamin C, De Mouzon J. Selective prescribing of third generation oral contraceptives (OCs). Contraception 1996;54:55-6
15. 15. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolisrn and the use of third generation progestagens: role of bias in observational research. Contraception 1996;54:5-13
16. 16. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8
17. 17. Lidegaard Ø. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand 1997;76:252-60
18. 18. Lewis MA. The epidemiology of oral contraceptive use: a critical review of studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 1998; 179:1086-97
19. 19. IFFS. Consensus conference on combination oral contraceptives and cardiovascular disease. Fertil Steril 1999;71:1S-6S
20. 20. Todd JC, Lawrenson R, Farmer RDT, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 1999;14:1500-5
21. 21. Farmer RDT, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998;57:67-70
22. 22. Farmer RDT, Lawrenson RA, Todd JC, Williams TJ, MacRae KD. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK MediPlus Database. Hum Reprod Update 1999;5:688-706
23. 23. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. Contraception 1998;57:291-301
24. 24. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6
25. 25. Suissa S. New analyses of the Transnational study data: the risk of venous thromboembolism among repeat users and switchers of newer oral contraceptives. Hum Reprod 2000; in press
26. 26. Lewis MA, MacRae KD, Kuhl-Habich D, Bruppacher R, Heinemann LAJ, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-9
27. 27. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999;159:65-70
28. 28. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127-8
29. 29. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptives and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997;177:887-91
30. 30. Walker AM. Newer oral contraceptives and the risk of thromboembolism. Contraception 1998;57:169-81
31. 31. Jick H, Jick SS, Myers MW, Vasilakis C. Third generation oral contraceptives and venous thrombosis. Lancet 1997;349:732-3
32. 32. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third generation oral contraceptives and venous thrombosis. Lancet 1997;349:731
33. 33. Poulter NR, Chang CL, Marmot M, Farley TM, Meirik O. Third generation oral contraceptives and venous thrombosis. Lancet 1997;349:732
34. 34. Weiss NS. Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives. Contraception 1997;55:189-90
35. 35. Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FH, Rosendaal FR. Risk of oral contraceptives and recency of market introduction. Contraception 1997;55-191-2
36. 36. Farley TMM, Meirik O, Marmot MG, Chang CL, Poulter NR. Oral contraceptives and risk of venous thromboembolism: impact of duration of use. Contraception 1998;57:61-5
37. 37. Farmer RDT, Lawrenson RA. Third generation oral contraceptives and venous thrombosis. Lancet 1997; 349:733
38. 38. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999;59:79-83
39. 39. Lewis MA, Spitzer WO. The role of bias in observational studies on oral contraceptives. Contraception 1997; 55:192-4
40. 40. Suissa S, Spitzer WO. Methodologic limitations in comparing the risks of newer oral contraceptives. Contraception 1998;57:64-5
41. 41. Villa P, Aznar J, Mira Y, Fernandez MA, Vaya A. Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis. Lancet 1996;347:397
42. 42. Plu-Bureau G, Amiral J, Guize L, Scarabin PY. Safety of combined oral contraceptive pills. Lancet 1996;347:549
43. 43. Vandenbroucke JP, Rosendaal FR. End of the line for 'third-generation-pill' controversy? Lancet 1997; 349:1113-14
44. 44. Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999;82:601-9
45. 45. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for thrombosis (Leiden Thrombophilia Study). Blood 1995;85: 2756-61
46. 46. Faioni EM, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci PM. Free protein S deficiency is a risk factor for venous thrombosis. Thromb Haemost 1997;78: 1343-6
47. 47. Liberti G, Bertina RM, Rosendaal FR. Hormonal state rather than age influenced the cut-off values of protein S. Re-evaluation of the thrombotic risk associated with protein S deficiency in the Leiden Thrombophilia study. Thromb Haemost 1999;Suppl:214-15
48. 48. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993;13:1829-36
49. 49. Heinrich J, Balleisen L, Schulte H, Assmann G, Loo J van de. Fibrinogen and factor VII in the prediction of coronary risk. Arterioscler Thromb 1994;14:54-9
50. 50. Meade TW, Brzovic M, Chakrabarti RR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart study. Lancet 1986;2:533-7
51. 51. Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJ Med 1994;87:403-6
52. 52. Koster T, Rosendaal FR, Reitsma PH, Velden PA van der, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719-22
53. 53. Janssen MCH, Verbruggen BW, Hark PJC, Novakova IRO. Factor VIIa determination compared to D-dimer in diagnosis of DVT. Thromb Res 1997;86: 423-6
54. 54. Rosing J, Tains G, Thomasson MC, et al.. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol 1997;97:233-8
55. 55. Schramm W, Heinemann LAJ. Oral contraceptives and venous thromboembolism: acquired APC resistance? Br J Haematol 1997;98:491-2
56. 56. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999;105:88-94
57. 57. Tans G, Rosendaal FR, Curvers J, Thomassen M, Bertina RM, Rosing J. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999:Suppl:202-3
58. 58. Heinemann LAJ, Assmann A, Spannagl M, et al. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 1998;58:321-2
59. 59. Visser MCH de, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-6
60. 60. Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR. Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet 1996;348: 401-2
61. 61. Thomas SHL. Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales. Lancet 1996;348:401
62. 62. Lunsen H van. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996;348:1095-6
63. 63. Cohen J. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996;348:1096
64. 64. Farmer RDT, Lewis MA. Oral contraceptives and mortality from venous thromboembolism. Lancet 1996; 348:1096-7
65. 65. Farmer RDT, Newson RB, MacRae K, Lawrenson RA, Tyrer F. Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives. J Epidemiol Commun Health 1997;51:630-5
66. 66. Mellemkjaer L, Sorensen HT, Dreyer L, Olsen J, Olsen JH. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95. Br Med J 1999;319:820-1
67. 67. Andersen BS, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium -an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998;77:170-3
68. 68. Wiholm BE, Olsson S, Moore N, Wood S. Spontaneous reporting systems outside the United States. In Strom BL, ed. Pharmacoepidemiology. Chichester, UK: John Wiley & Sons, 1994:139-56
69. 69. Office for National Statistics. Legal abortions, June quarter 1996. ONS Monitor AB 97/1, London 1997
70. 70. Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997;55:11-14
71. 71. Statistisches Bundesamt. Ergebnisse der Schwangerschaftsabbruchstatistik nach der gesetzlichen Neuregelung der Statistik für das Jahr 1996. Wiesbaden, 23 May 1997